AV
Albert Vilella, PhD.
@albertvilella.bsky.social
Bioinformatics Scientist / Next Generation Sequencing / Single Cell and spatial biology / Next Generation Proteomics / Liquid Biopsy/ SynBio / Compute Acceleration // albertvilella.substack.com
2.8k followers6k following483 posts
The Johnson and Johnson Phase III MARIPOSA trial of the activity of Rybrevant and Lazcluze as anti-EGFR therapy for NSCLC demonstrated significant improvement of progression-free survival compared to Tagrisso. www.genomeweb.com/cancer/liqui...
AV
Albert Vilella, PhD.
@albertvilella.bsky.social
Bioinformatics Scientist / Next Generation Sequencing / Single Cell and spatial biology / Next Generation Proteomics / Liquid Biopsy/ SynBio / Compute Acceleration // albertvilella.substack.com
2.8k followers6k following483 posts